FISCHER vs RUBICON: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. FISCHER MEDICAL VENTURE L shows a lower P/E, a higher dividend yield and faster revenue growth, while RUBICON RESEARCH shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
FISCHER leads 7; RUBICON leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | FISCHER | RUBICON |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Equipment & Supplies | Pharmaceuticals |
Price
| Metric | FISCHER | RUBICON |
|---|---|---|
| Live Price | ₹33.74 | ₹1,791.8 |
| Day Change | 0.72% | 1.42% |
| Volume | 1.53 L | 1.17 L |
| 52-Week High | ₹124.7 | ₹1,899 |
| 52-Week Low | ₹31.05 | ₹570.75 |
| Distance from 52W High | -72.94% | -5.65% |
Valuation
| Metric | FISCHER | RUBICON |
|---|---|---|
| Market Cap | ₹2,194 Cr | ₹29,632 Cr |
| P/E Ratio | 72.17x | 102.12x |
| P/B Ratio | 5.66x | 22.84x |
| EPS | ₹0.45 | ₹4.99 |
| Book Value | ₹5.96 | ₹77.93 |
| Dividend Yield | 0.15% | 0.08% |
Growth
| Metric | FISCHER | RUBICON |
|---|---|---|
| Revenue Growth (TTM YoY) | 98.7% | 43.5% |
| EPS Growth (TTM YoY) | 0% | 96.6% |
| Qtr Sales Growth | 11,250.98% | -19.95% |
| Qtr Profit Growth | 208.2% | -2.75% |
Profitability & Leverage
| Metric | FISCHER | RUBICON |
|---|---|---|
| ROE | 8.05% | 19.14% |
| ROCE | 7.89% | 20.49% |
| Net Margin | 6.79% | 13.48% |
| Operating Margin | 16.99% | 20.68% |
| Debt to Equity | 0.19x | 0.2x |
Shareholding
As of Aug 2026 • change vs previous quarter| Metric | FISCHER | RUBICON |
|---|---|---|
| Promoter Holding | 12.31%▲ 0.85 pp | 23.93%▼ 0.04 pp |
| FII Holding | 5.57%▲ 0.09 pp | 7.52%▼ 0.02 pp |
| DII Holding | 1.26%▼ 0.09 pp | 9.43%▼ 0.59 pp |
| Public Holding | 30.09%▼ 0.93 pp | 23.3%▲ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FISCHER MEDICAL VENTURE L and RUBICON RESEARCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.